Castle Biosciences, Inc. (CSTL)
NASDAQ · Healthcare
Castle Biosciences, Inc. EBITDA 2018–2025
Castle Biosciences, Inc. annual/quarterly ebitda history and growth rate from 2020 to 2026. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Castle Biosciences, Inc. ebitda for the quarter ending March 31, 2026 was -14.5 M, a 888.56% decrease year-over-year.
- Castle Biosciences, Inc. ebitda for the twelve months ending March 31, 2026 was -43.4 M.
- Castle Biosciences, Inc. annual ebitda for 2025 was -2.0 M, a 108.27% decrease from 2024.
- Castle Biosciences, Inc. annual ebitda for 2024 was 24.7 M, a 144.33% decrease from 2023.
- Castle Biosciences, Inc. annual ebitda for 2023 was -55.6 M, a 10.70% decrease from 2022.
- Castle Biosciences, Inc. annual ebitda for 2022 was -62.3 M.
EBITDA
TRAILING 12 MONTHS · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Castle Biosciences, Inc. EBITDA — FAQ
Castle Biosciences, Inc. (CSTL) ebitda over the last 8 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see CSTL's ebitda history?
The chart and table above show Castle Biosciences, Inc.'s ebitda by year and by quarter, including the growth rate.